Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Nektar Therapeutics : Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer SITC...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/17/2016 | 10:10pm CET

Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer SITC 2016 Annual Meeting

By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Nektar Therapeutics (Nasdaq: NKTR) announced that new Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting. NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells and Natural Killer (NK) cell abundance directly in the tumor micro-environment and increase expression of PD-1 on these immune cells. The results were presented by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in an oral presentation during today's session entitled "New Cancer Immunotherapy Agents in Development."

Interim results presented were from the ongoing Phase 1 dose-escalation, first-in-human, trial of single-agent NKTR-214 in patients with locally advanced or metastatic solid tumors, including melanoma, renal cell carcinoma (RCC), bladder, colorectal and other solid tumor cancers. A total of 20 patients were treated in four separate every three-week (q3w) dose cohorts (ranging from 0.003 mg/kg q3w to 0.012 mg/kg q3w) with 18 of these patients evaluable for anti-tumor activity. Based upon encouraging anti-tumor activity and tolerability of NKTR-214 observed at the 0.006 mg/kg q3w dose, an every two week (q2w) cohort of the 0.006 mg/kg dose began enrolling in September 2016 with an additional 5 patients enrolled to this cohort, all of which are continuing on therapy (see also Nektar Therapeutics).

"NKTR-214 resulted in robust activation of the immune system and encouraging anti-tumor activity, including a partial response observed in a patient who continues to be treated with NKTR-214," said Dr. Ivan Gergel, Senior Vice President, Drug Development & Chief Medical Officer of Nektar. "NKTR-214 was also well tolerated in patients when administered as an every two-week or every three-week outpatient therapy. We are very encouraged by the clinical profile emerging for NKTR-214 and the totality of the data from this ongoing single-agent trial of NKTR-214."

Keywords for this news article include: Oncology, Immunotherapy, Cancer Therapy, Clinical Research, Drugs and Therapies, Nektar Therapeutics, Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEKTAR THERAPEUTICS
11/17 NEKTAR THERAPEUTICS : Presents New Clinical Data from Ongoing Phase 1 Dose-Escal..
11/14 NEKTAR THERAPEUTICS : to Present at Jefferies 2016 Global Healthcare Conference ..
11/09 NEKTAR THERAPEUTICS : Presents New Clinical Data from Ongoing Phase 1 Dose-Escal..
11/09 NEKTAR THERAPEUTICS : Other Events (form 8-K)
11/04 NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
11/03 NEKTAR THERAPEUTICS : reports 3Q loss
11/03 NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
11/03 NEKTAR THERAPEUTICS : Reports Financial Results for the Third Quarter of 2016
11/03 NEKTAR THERAPEUTICS : to Hold Investor & Analyst Event at 2016 Society for Immun..
11/02 NEKTAR THERAPEUTICS : to Announce Financial Results for the Third Quarter 2016 o..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/03 Nektar Therapeutics' (NKTR) CEO Howard Robin on Q3 2016 Results - Earnings Ca..
11/03 Nektar Therapeutics beats by $0.04, beats on revenue
11/02 Notable earnings after Thursday?s close
10/26 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Cree, mcc, reed, erc
10/19 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
Advertisement
Financials ($)
Sales 2016 169 M
EBIT 2016 -112 M
Net income 2016 -149 M
Debt 2016 109 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 11,8x
EV / Sales 2017 10,0x
Capitalization 1 891 M
More Financials
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 20,3 $
Spread / Average Target 64%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS-26.59%1 891
INCYTE CORPORATION-7.86%19 219
QUINTILES IMS HOLDINGS..6.32%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.48.64%9 442
LONZA GROUP AG11.34%9 247
More Results